Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study
Author:
Affiliation:
1. Quantitative Clinical Pharmacology; AstraZeneca; Waltham MA USA
2. Scientific Partnering & Alliances; Innovative Medicines; AstraZeneca Cambridge UK
3. Scientific Partnering & Alliances; Innovative Medicines; AstraZeneca Waltham MA USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.680/fullpdf
Reference20 articles.
1. The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study;Litman;J Clin Psychopharmacol,2014
2. NK3 receptor antagonists: the next generation of antipsychotics?;Spooren;Nat Rev Drug Dis,2005
3. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (Talnetant): potential therapeutic utility in the treatment of schizophrenia;Dawson LA;Neuropsychopharmacology,2008
4. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvement in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics;Dawson LA;Eur J Pharm,2010
5. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria;March;Hum Reprod,2010
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications;Current Medicinal Chemistry;2020-03-27
2. Introduction;Structure–Activity Relationships for Development of Neurokinin-3 Receptor Antagonists;2020
3. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact;Bioorganic & Medicinal Chemistry;2019-05
4. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch;Journal of Pharmacokinetics and Pharmacodynamics;2019-01-19
5. Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet;European Journal of Pharmaceutical Sciences;2017-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3